World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
36057
World Ranking
14411
National Ranking
1332

Overview

Claire N. Harrison is affiliated with Guy's and St Thomas' NHS Foundation Trust in the United Kingdom. Their research primarily focuses on medicine, with significant contributions in genetics, hematology, molecular biology, rheumatology, and oncology.

The scientist has been involved in the study of several main topics, including:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Kruppel-like factors research
  • Eosinophilic Disorders and Syndromes
  • Multiple Myeloma Research and Treatments
  • Hemoglobinopathies and Related Disorders

Frequent co-authors in Claire Harrison's work include:

  • Jean-Jacques Kiladjian
  • Ruben A. Mesa
  • Srđan Verstovšek
  • Alessandro M. Vannucchi
  • John Mascarenhas

Publications by Claire Harrison have appeared in several well-known venues, such as:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • HemaSphere
  • British Journal of Haematology
  • Leukemia

Significant recent papers include:

  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022), published in Leukemia
  • Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (2023), published in The Lancet
  • Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study (2020), published in The Lancet Haematology
  • Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure (2020), published in American Journal of Hematology
  • Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial (2023), published in Journal of Clinical Oncology

Best Publications

  • Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

    J. Nangalia;C.E. Massie;E.J. Baxter;F.L. Nice

  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

    Claire Harrison;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali;Heinz Gisslinger

  • JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

    Linda M. Scott;Wei Tong;Ross L. Levine;Mike A. Scott

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

    Harrison Cn;Campbell Pj;Buck G;Wheatley K

  • Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi

  • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

    Peter J Campbell;Linda M Scott;Georgina Buck;Keith Wheatley

  • Effect of Mutation Order on Myeloproliferative Neoplasms

    Christina A. Ortmann;David G. Kent;Jyoti Nangalia;Yvonne Silber

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Jacob Grinfeld;Jyoti Nangalia;E Joanna Baxter;David C Wedge

  • Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    C.N Harrison;A.M. Vannucchi;J.-J. Kiladjian;H.K. Al-Ali

  • MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

    Philip A. Beer;Peter J. Campbell;Linda M. Scott;Anthony J. Bench

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Animesh Pardanani;Claire Harrison;Jorge E. Cortes;Francisco Cervantes

  • Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis

    Mary F. McMullin;D. Bareford;P. Campbell;A. R. Green

  • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

    Francisco Cervantes;Alessandro M. Vannucchi;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

    Robyn Scherber;Amylou C. Dueck;Peter Johansson;Tiziano Barbui

  • A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis

    Melanie J. Percy;Quan Zhao;Adrian Flores;Claire Harrison

  • Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

    Peter J Campbell;E Joanna Baxter;Philip A Beer;Linda M Scott

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Francesco Passamonti
Francesco Passamonti University of Milan
Mary Frances McMullin
Mary Frances McMullin Queen's University Belfast
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Francisco Cervantes
Francisco Cervantes University of Barcelona
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Giovanni Barosi
Giovanni Barosi University of Pavia
Amylou C. Dueck
Amylou C. Dueck Mayo Clinic
Alessandro Rambaldi
Alessandro Rambaldi University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways to a career in medicine can open doors to a wide range of vital roles in healthcare. Online education offers flexibility for students who need to balance their studies with work or family obligations. One popular entry point is through medical billing and coding online schools, which provide foundational skills for administrative healthcare positions and often offer financial aid.

For those interested in nursing, it’s possible to find a nursing school that doesn't require teas exams, making admission more accessible for aspiring nurses. Students aiming for leadership opportunities in the healthcare sector might consider enrolling in a health care administration degree online to gain skills in management, policy, and operations.

For registered nurses seeking career advancement, there are convenient bridge programs like asn to np programs, which enable nurses to become nurse practitioners with advanced training. These varied options allow students to find the right fit for their career goals within the ever-growing healthcare field.

Best Scientists Citing Claire N. Harrison

Trending Scientists